Game-Changing Evolve Formulas Products Soon to Disrupt the Oregon Cannabis Market

—NanoSphere Health Sciences Signs Letter of Intent with Cascade Pure—

DENVER (November 13, 2018) – NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF), the biotechnology leader behind the patented NanoSphere Delivery System™, today signed a new letter of intent with Cascade Pure, LLC, which will bring Evolve Formulas products to the Oregon medical and recreational cannabis markets. The brand’s pioneering product, the Evolve Formulas Transdermal NanoSerum™, will hit dispensary shelves in the first quarter of 2019.

“Coming on the heels of Evolve Formulas’ California debut, we are eager to continue our west coast expansion by entering Oregon, with additional markets soon to follow,” said Robert Sutton, Chairman and CEO of NanoSphere Health Sciences and Evolve Formulas. “Cascade Pure shares NanoSphere’s mission to bring revolutionary solutions to the cannabis industry from seed to sale, making them an ideal partner fit. Together, we will drive innovation and set a new precedent for quality, safety and precision in cannabis-infused products.”

“Nanotechnology is the future of cannabis, and NanoSphere Health Sciences has mastered the art with its industry-leading NanoSphere Delivery System™,” said Cascade Pure Co-Founder and CEO Edward Bonn. “We are proud to break ground with NanoSphere and foster Evolve Formulas’ growth in a new market of consumers looking for a unique, discreet and approachable option that provides unparalleled relief.”

Cascade Pure, LLC will provide a state-of-the-art cultivation and processing facility located in Bend, Oregon. Their conceptual plan is designed around the Smart Grow Systems solutions, and will be modified to fit NanoSphere’s needs. Their proprietary building system revolutionizes indoor cultivation and processing facilities. NanoSphere plans to take this partnership into additional markets in the future.

Cascade Pure, LLC is an Oregon-based company formed to operate the production of genetically superior, pathogen and bug-free clones as well as a seed bank second to none, utilizing tissue culture technology. Cascade Pure offers over 800+ strains of rare, high value and in-demand stains. It also has the ability to offer limited exclusive genetic strains to preferred customers. Evolve Formulas will be the sole brand that Cascade Pure distributes. 

For more information on Nanosphere Health Sciences, Inc. or to schedule an interview, please contact Gabrielle Wesseldyk at media@nanospherehealth.com or 212-255-0945.

###

On behalf of the Board
Robert Sutton, Chairman and CEO
Office: 720-520-4282
Email: rsutton@nanospherehealth.com

Investor Contact:
Victor Goncalves, Executive Vice President
Mobile: 204-997-5517
E-mail: vgoncalves@nanospherehealth.com

NanoSphere’s Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences, Inc. is a biotechnology firm specializing in the creation of the patented NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. Covered by U.S. Patent No. 10,028,919 and U.S. Patent No. 9,925,149, NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. NanoSphere was awarded the 2018 Frost and Sullivan Technology Innovation Award and was recognized by ACQ5 Global Awards as Company of the Year for Nano-Biotechnology, Innovative Company of the Year for Healthcare, and its CEO Robert Sutton was honored as Gamechanger of the Year. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

Samuel TheilComment